CryoPort (NASDAQ:CYRX) Insider Edward Zecchini Sells 1,400 Shares of Stock

CryoPort, Inc. (NASDAQ:CYRX) insider Edward Zecchini sold 1,400 shares of CryoPort stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $15.23, for a total value of $21,322.00. Following the sale, the insider directly owned 109,719 shares of the company’s stock, valued at approximately $1,671,020.37. This trade represents a 1.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

CryoPort Stock Up 1.7%

Shares of NASDAQ CYRX opened at $14.62 on Friday. The business has a fifty day simple moving average of $12.42 and a two-hundred day simple moving average of $10.33. The firm has a market cap of $736.85 million, a PE ratio of 10.83 and a beta of 1.90. CryoPort, Inc. has a twelve month low of $6.16 and a twelve month high of $16.73.

CryoPort (NASDAQ:CYRX) last issued its earnings results on Monday, May 4th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The firm had revenue of $47.80 million for the quarter, compared to the consensus estimate of $44.86 million. CryoPort had a net margin of 41.57% and a negative return on equity of 7.92%. On average, research analysts expect that CryoPort, Inc. will post -0.85 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Millennium Management LLC raised its position in shares of CryoPort by 23.8% in the 4th quarter. Millennium Management LLC now owns 3,244,802 shares of the company’s stock worth $31,150,000 after acquiring an additional 623,896 shares in the last quarter. Vanguard Group Inc. raised its position in shares of CryoPort by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,858,031 shares of the company’s stock worth $27,094,000 after acquiring an additional 69,550 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of CryoPort by 0.6% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,495,683 shares of the company’s stock worth $12,384,000 after acquiring an additional 8,280 shares in the last quarter. UBS Group AG raised its position in shares of CryoPort by 6.8% in the 4th quarter. UBS Group AG now owns 1,421,884 shares of the company’s stock worth $13,650,000 after acquiring an additional 90,363 shares in the last quarter. Finally, Mak Capital One LLC grew its stake in CryoPort by 46.6% during the 4th quarter. Mak Capital One LLC now owns 1,199,225 shares of the company’s stock worth $11,513,000 after buying an additional 381,063 shares during the last quarter. 92.90% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CYRX. Jefferies Financial Group set a $13.50 target price on CryoPort in a research report on Monday. KeyCorp boosted their price target on CryoPort from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. BTIG Research boosted their price target on CryoPort from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Guggenheim boosted their price target on CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Finally, Wall Street Zen raised CryoPort from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Eight analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $15.11.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.